These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21536130)

  • 41. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
    Hu YC; Komorowski RA; Graewin S; Hostetter G; Kallioniemi OP; Pitt HA; Ahrendt SA
    Clin Cancer Res; 2003 Sep; 9(11):4165-71. PubMed ID: 14519641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thymidylate synthase polymorphism and microsatellite instability: association in colorectal cancer.
    Calascibetta A; Rausa L; Gullotti L; Buettner R; Sanguedolce R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1377-9. PubMed ID: 15571262
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
    Baroudi O; Baroudi T; Omrane I; Moussa A; Mezlini A; Ayari H; Guermazi S; Bahloul A; Bouzaienne H; Uhrhammer N; Bignon YJ; El-Gaaied AB; Bougatef K
    Med Oncol; 2014 Feb; 31(2):825. PubMed ID: 24415354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Casazza S; Antonelli G; Tunesi G; Baldo C; Lionetto R; Maley F; Sobrero A
    J Clin Oncol; 1999 Jun; 17(6):1760-70. PubMed ID: 10561213
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
    de Bock CE; Garg MB; Scott N; Sakoff JA; Scorgie FE; Ackland SP; Lincz LF
    Pharmacogenomics J; 2011 Aug; 11(4):307-14. PubMed ID: 20531375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thymidylate synthase expression pattern is a prognostic factor in patients of colorectal cancer treated with 5-fluorouracil.
    Fernández-Contreras ME; Jiménez De Ayala B; García De Paredes ML; Velasco A; Majano PL; Palacios J; Gamallo C
    Int J Oncol; 2004 Oct; 25(4):877-85. PubMed ID: 15375535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
    Wong NA; Brett L; Stewart M; Leitch A; Longley DB; Dunlop MG; Johnston PG; Lessells AM; Jodrell DI
    Br J Cancer; 2001 Dec; 85(12):1937-43. PubMed ID: 11747337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
    Fernández-Contreras ME; Sánchez-Hernández JJ; Guijarro M; Gisbert JP; Rivas N; García de Paredes ML; Hinojar-Gutiérrez A; Gamallo C
    Oncol Rep; 2010 May; 23(5):1393-400. PubMed ID: 20372856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival.
    Tanaka-Nozaki M; Tajiri T; Tanaka N; Furukawa K; Takasaki H; Yoshimura K; Suzuki H; Naito Z; Sugizaki Y; Merk HF; Blömeke B; Kato S
    Oncol Rep; 2003; 10(5):1425-9. PubMed ID: 12883718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Amatori F; Di Paolo A; Del Tacca M; Fontanini G; Vannozzi F; Boldrini L; Bocci G; Lastella M; Danesi R
    Pharmacogenet Genomics; 2006 Nov; 16(11):809-16. PubMed ID: 17047489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
    Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
    Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors.
    Mini E; Biondi C; Morganti M; Napoli C; Mazzoni P; Cianchi F; Tonelli F; Cortesini C; Capaccioli S; Ficari F; Quattrone A; Rossi S; Mazzei T
    Oncol Res; 1999; 11(9):437-45. PubMed ID: 10821538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
    Kiss-László Z; Nagy B; Thurzó L; Szabó J
    Magy Onkol; 2006; 50(1):33-7. PubMed ID: 16617381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer.
    Cui YH; Liu TS; Zhuang RY; Gao HJ; Li H
    J Dig Dis; 2009 May; 10(2):118-23. PubMed ID: 19426394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy.
    Kawakami K; Graziano F; Watanabe G; Ruzzo A; Santini D; Catalano V; Bisonni R; Arduini F; Bearzi I; Cascinu S; Muretto P; Perrone G; Rabitti C; Giustini L; Tonini G; Pizzagalli F; Magnani M
    Clin Cancer Res; 2005 May; 11(10):3778-83. PubMed ID: 15897576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
    Villafranca E; Okruzhnov Y; Dominguez MA; García-Foncillas J; Azinovic I; Martínez E; Illarramendi JJ; Arias F; Martínez Monge R; Salgado E; Angeletti S; Brugarolas A
    J Clin Oncol; 2001 Mar; 19(6):1779-86. PubMed ID: 11251009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.